OBJECTIVE: To determine the natural course of sporadic adult-onset lower motor neuron syndrome in a long-term prospective study of patients with the syndrome. DESIGN: Inception cohort with a follow-up of 72 months. SETTING: Three university hospitals in the Netherlands (referral centers for neuromuscular diseases). PATIENTS: Thirty-two patients were classified as having the following phenotypes according to previously defined criteria: progressive muscular atrophy (PMA; 10 patients), segmental distal muscular atrophy (8 patients), and segmental proximal muscular atrophy (14 patients). A disease duration of at least 4 years was chosen to exclude most patients with amyotrophic lateral sclerosis (ALS). MAIN OUTCOME MEASURES: Muscle strength, functional impairment, and respiratory function were assessed at 0, 6, 12, 18, and approximately 72 months. RESULTS: The diagnosis had to be changed to ALS in 3 patients (classified at inclusion as PMA in 2 patients and segmental proximal muscular atrophy in 1) owing to the development of upper motor neuron signs in 2 patients and familial ALS in 1. The remaining 8 patients with PMA showed further deterioration, and the other 24 patients remained more or less stable during long-term follow-up. Respiratory insufficiency developed in 6 of the 11 patients with ALS or PMA, 5 of whom died. CONCLUSIONS: Patients with lower motor neuron syndromes and a disease duration of at least 4 years usually have a favorable prognosis if muscle involvement has a segmental distribution. In patients with a generalized phenotype, progression is relentlessly progressive and eventually leads to death due to respiratory insufficiency.
OBJECTIVE: To determine the natural course of sporadic adult-onset lower motor neuron syndrome in a long-term prospective study of patients with the syndrome. DESIGN: Inception cohort with a follow-up of 72 months. SETTING: Three university hospitals in the Netherlands (referral centers for neuromuscular diseases). PATIENTS: Thirty-two patients were classified as having the following phenotypes according to previously defined criteria: progressive muscular atrophy (PMA; 10 patients), segmental distal muscular atrophy (8 patients), and segmental proximal muscular atrophy (14 patients). A disease duration of at least 4 years was chosen to exclude most patients with amyotrophic lateral sclerosis (ALS). MAIN OUTCOME MEASURES: Muscle strength, functional impairment, and respiratory function were assessed at 0, 6, 12, 18, and approximately 72 months. RESULTS: The diagnosis had to be changed to ALS in 3 patients (classified at inclusion as PMA in 2 patients and segmental proximal muscular atrophy in 1) owing to the development of upper motor neuron signs in 2 patients and familial ALS in 1. The remaining 8 patients with PMA showed further deterioration, and the other 24 patients remained more or less stable during long-term follow-up. Respiratory insufficiency developed in 6 of the 11 patients with ALS or PMA, 5 of whom died. CONCLUSIONS:Patients with lower motor neuron syndromes and a disease duration of at least 4 years usually have a favorable prognosis if muscle involvement has a segmental distribution. In patients with a generalized phenotype, progression is relentlessly progressive and eventually leads to death due to respiratory insufficiency.
Authors: Felix Geser; Beth Stein; Michael Partain; Lauren B Elman; Leo F McCluskey; Sharon X Xie; Vivianna M Van Deerlin; Linda K Kwong; Virginia M-Y Lee; John Q Trojanowski Journal: Acta Neuropathol Date: 2011-01-12 Impact factor: 17.088
Authors: John Ravits; Stanley Appel; Robert H Baloh; Richard Barohn; Benjamin Rix Brooks; Lauren Elman; Mary Kay Floeter; Christopher Henderson; Catherine Lomen-Hoerth; Jeffrey D Macklis; Leo McCluskey; Hiroshi Mitsumoto; Serge Przedborski; Jeffrey Rothstein; John Q Trojanowski; Leonard H van den Berg; Steven Ringel Journal: Amyotroph Lateral Scler Frontotemporal Degener Date: 2013-05 Impact factor: 4.092
Authors: Martin R Turner; Orla Hardiman; Michael Benatar; Benjamin R Brooks; Adriano Chio; Mamede de Carvalho; Paul G Ince; Cindy Lin; Robert G Miller; Hiroshi Mitsumoto; Garth Nicholson; John Ravits; Pamela J Shaw; Michael Swash; Kevin Talbot; Bryan J Traynor; Leonard H Van den Berg; Jan H Veldink; Steve Vucic; Matthew C Kiernan Journal: Lancet Neurol Date: 2013-03 Impact factor: 44.182
Authors: Marka van Blitterswijk; Lotte Vlam; Michael A van Es; W-Ludo van der Pol; Eric A M Hennekam; Dennis Dooijes; Helenius J Schelhaas; Anneke J van der Kooi; Marianne de Visser; Jan H Veldink; Leonard H van den Berg Journal: PLoS One Date: 2012-11-14 Impact factor: 3.240